Development of an engineered extracellular vesicles-based vaccine platform for combined delivery of mRNA and protein to induce functional immunity.

ABSTRACT: mRNA incorporated in lipid nanoparticles (LNPs) became a new class of vaccine modality for induction of immunity against COVID-19 and ushered in a new era in vaccine development. Here, we report a novel, easy-to-execute, and cost effective engineered extracellular vesicles (EVs)-based combined mRNA and protein vaccine platform (EV^X-M+P vaccine) and explore its utility in proof-of-concept immunity studies in the settings of cancer and infectious disease. As a first example, we engineered EVs, natural nanoparticle carriers shed by all cells, to contain ovalbumin mRNA and protein (EV^OvaM+P vaccine) to serve as cancer vaccine against ovalbumin-expressing melanoma tumors. EV^OvaM+P administration to mice with established melanoma tumors resulted in tumor regressi

SUBMITTER: Luo X 

PROVIDER: S-EPMC11978227 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature